

# A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET

NCT06592989

---

Status	RECRUITING
Sponsor	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Enrollment	20 participants

## Plain Language Summary

---

This study is testing whether combining two targeted drugs — sorafenib and gefitinib — can benefit patients with pancreatic neuroendocrine tumors (a rare type of pancreatic tumor) whose cancer has kept growing despite previous treatments.

**\*\*You may be eligible if...\*\***

- You are between 18 and 80 years old
- You have been diagnosed with a pancreatic neuroendocrine tumor, confirmed by biopsy or cell testing
- Your cancer progressed after previous treatments (such as hormone analogs, targeted therapy, or chemotherapy)
- There is at least one measurable tumor on imaging
- Your last treatment ended at least 7 days ago
- Your expected survival is at least 12 weeks
- Your liver, kidneys, and bone marrow are functioning adequately

**\*\*You may NOT be eligible if...\*\***

- You have another active cancer
- You are pregnant or breastfeeding
- You have serious heart, liver, or kidney problems

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (9)

- Patients must have a full understanding of this study and voluntarily sign an informed consent form;
  - Age e 18 years old and age d 80 years old;
  - Patients with pancreatic neuroendocrine tumors diagnosed by histopathology or cytology, who have progressed after previous treatments such as SSA, targeted therapy, and chemotherapy (all grades of pancreatic neuroendocrine tumors and neuroendocrine cancers are allowed to be included);
  - According to the criteria for evaluating the efficacy of solid tumors (RECIST V1.1), there should be at least one measurable lesion;
  - At least 7 days have passed since the end of the last systemic treatment, and palliative radiotherapy for localized areas is allowed. It has been completed for more than 4 weeks;
- ... and 4 more (see full listing online)

### Exclusion (10)

- Other malignant tumors have been diagnosed in the past 5 years, except for effectively treated skin basal cell carcinoma, skin squamous cell carcinoma, or effectively resected cervical carcinoma in situ, breast cancer;
- Simultaneously receiving other investigational drugs or approved or investigational anti-tumor treatments;

---

<https://clinicaltrials.gov/study/NCT06592989>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

- Patients with contraindications to experimental drugs (such as active bleeding, ulcers, intestinal perforation, intestinal obstruction, uncontrolled hypertension, III-IV grade heart failure, within 30 days after major surgery, severe liver and kidney dysfunction, etc.);
  - The patient currently has any diseases or conditions that affect drug absorption, or the patient is unable to take oral medication;
  - Confirmed allergy to any component of the investigational drug and/or its excipients;
- ... and 5 more (see full listing online)

## Locations (1 total)

---

Shanghai General Hospital, Shanghai, Shanghai Municipality, China